Authors
Fu-Ying Yang, Di Wang, Liu Ye, Yi-Meng Zhang, Li-Jun Liang, Yan-Fei Zhang, Yi-Shuai Tan, Aikede Alifu, Meng-Yao Lv, Fen-Rong Xie, Yan-Yun Gao, Jiao-Jiao Xu, Yang-Tong Liu, Cong Wang, Bing-Qing Xu, Yan-Zhi Bai, Zhi-Xiao Liao, Yu-Tao Liu, Gui-Zhen Wang, Guang-Biao Zhou
Published in
Cancer letters. Pages 218967. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
To determine the cancer-initiating activity of oncoprotein CIP2A, which is overexpressed in a majority of cancers and promotes cell growth by stabilizing MYC, we established an alveolar type 2 cell-specific CIP2A transgenic mouse line. Among 114 transgenic mice aged 12 months or older, 23 (20.2%) developed lung adenocarcinoma (LUAD)-like disease, significantly higher than in the control mice (3/63, 4.8%). Multi-omic studies revealed enrichment of the oxidative phosphorylation (OXPHOS) pathway in tumor tissues from transgenic mice. CIP2A upregulated phosphorylation of FOXO3A (p-FOXO3A S253) by inhibiting phosphatase PP2A-B56α and promoted FOXO3A mitochondrial translocation. CIP2A-FOXO3A reshaped mitochondrial morphology, activated mitochondrial DNA transcription, and enhanced complexes IV/V activities. OXPHOS inhibitor repressed CIP2A-induced cell proliferation and tumor growth. Moreover, tobacco carcinogens upregulated CIP2A and p-FOXO3A S253 and significantly increased cancer incidence in CIP2A-transgenic mice. These data indicate that CIP2A plays a critical role in mitochondrial regulation and represents a promising therapeutic target for LUADs lacking actionable driver mutations.
PMID:
43014540
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0